<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Iranian Society of Radiology</PublisherName>
				<JournalTitle>Iranian Congress of Radiology</JournalTitle>
				<Issn>25885545</Issn>
				<Volume>38</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2023</Year>
					<Month>09</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>FDG PET/CT in Treatment Response Evaluation in Oncology</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>137</FirstPage>
			<LastPage>137</LastPage>
			<ELocationID EIdType="pii">179445</ELocationID>
			
<ELocationID EIdType="doi">10.22034/icrj.2023.179445</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Maryam</FirstName>
					<LastName>Mohammadzadeh</LastName>
<Affiliation>Associate Professor, Department of Radiology
Division of Neuroradiology and Head &amp; Neck Imaging
Sina Hospital, Tehran University of Medical Sciences</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>09</Month>
					<Day>19</Day>
				</PubDate>
			</History>
		    <Abstract>During this session traditional and new response criteria in oncologic imaging will be presented and discussed in details.
There will be detailed discussion and comparison of various response criteria including WHO, RESIST 1.0 , RESIST 1.1 and PERSIST which are among the most widely used response criteria in oncologic imaging and treatment planning. There will also be brief presentation of PET CT and it’s role in treatment response specially in equivocal cases . Finally there will be case presentation for better understanding of RESIST and PERSIST specially for academic interpretation of oncologic imaging.</Abstract>
</Article>
</ArticleSet>
